Recent advances in childhood acute lymphoblastic leukemia

Journal of the Formosan Medical Association

Volumn 103, Issue 2, 2004, Pages 85-95

  Pui, Ching Hon ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Gene expression profiling; Minimal residual disease; Pharmacogenetics

Indexed keywords

ALLOPURINOL; ANTICONVULSIVE AGENT; ANTILEUKEMIC AGENT; ANTIMETABOLITE; ASPARAGINASE; CARBAMAZEPINE; CYTARABINE; CYTOCHROME P450; DEXAMETHASONE; DIPYRONE; DRUG METABOLIZING ENZYME; FLUCONAZOLE; GLUCOCORTICOID; GYRASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MACROGOL; MERCAPTOPURINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PHENYTOIN; PREDNISONE; PROPOXUR; PYRROLE DERIVATIVE; RASBURICASE; UNINDEXED DRUG; URATE OXIDASE; VINCRISTINE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; BEHAVIOR DISORDER; BIOTECHNOLOGY; BLOOD TOXICITY; CHILDHOOD CANCER; CLINICAL TRIAL; COMPLICATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG RESPONSE; DRUG SPECIFICITY; DRUG TARGETING; DRUG TRANSPORT; GASTROINTESTINAL TOXICITY; GENE EXPRESSION PROFILING; GENE SILENCING; HOST; HUMAN; HYPERURICEMIA; LEUKEMIA CELL; LEUKEMOGENESIS; LIVER TOXICITY; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; MYCOSIS; MYOPATHY; PHARMACODYNAMICS; PHARMACOGENETICS; PROGNOSIS; PROTEOMICS; RELIABILITY; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT PLANNING; ACUTE LYMPHOCYTIC LEUKEMIA; CHILD; GENETICS; REMISSION;

CHILD; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; NEOPLASM, RESIDUAL; PHARMACOGENETICS; REMISSION INDUCTION;

EID: 2542484729     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Conter V, Aricò M, Valsecchi MG, et al: Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995. Leukemia 2001;14:2196-204.
2. Bürger B, Zimmermann M, Mann G, et al: Diagnostic cerebrospinal fluid (CSF) examination in children with acute lymphoblastic leukemia (ALL): Significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol 2003;21:184-8.
3. Gaynon PS, Trigg ME, Heerema NA, et al: Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000;14:2223-33.
4. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92. Leukemia 2000;14:2234-9.
5. Kamps WA, Bökkerink JPM, Hakvoort-Cammel FGAJ, et al:BFM-oriented treatment for children with acute lymphoblastic leukemia without crania irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia 2002; 16:1099-111.
6. Silverman LB, Gelber RD, Dalton VK, et al: Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97:1211-8.
7. Vilmer E, Suciu S, Ferster A, et al: Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: A CLCG-EORTC report. Leukemia 2000; 14:2257-66.
8. Schmiegelow K, Björk O, Glomstein A, et al: Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol 2003;21:1332-9.
9. Maloney KW, Shuster JJ, Murphy S, Pullen J, Camitta BA: Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. Leukemia 2000;14:2276-85.
10. Pui CH, Sandlund JT, Pei D, et al: Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA 2003; 290:2001-7
11. Eden OB, Harrison G, Richards S, et al: Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Leukemia 2000;14:2307-20.
12. Pui CH, Evans WE: Acute lymphoblastic leukemia. N ENgl J Med 1998;339:605-15.
13. Pui CH, Cheng C, leung W, et al: Extended follow-up of long-term survisors of childhood acute lymphoblastic leukemia. N Engl J Med 2003;349:640-9.
14. Aricò M, Valsecchi MG, Camitta B, et al: Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342:998-1006.
15. Pui Ch, Gaynon PS, Boyett JM, et al: Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal regions. Lancet 2002;359:1909-15.
16. Hanahan D, Weinberg R: The hallmarks of cancer. Cell 2000; 100:57-70.
17. Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukemia. N Engl J Med. In press 2004.
18. Vousden KH, Lu X: Live or let die: the cell's response to p53. Nat Rev cancer 2002;2:594-604.
19. Calero Moreno TM, Gustafsson G, Garwicz S, et al: Deletion of the Ink4-locus (the p16ink4a, p14ARF and p15ink4b genes) predicts relapse in children with ALL treated according to the Nordic protocols NOPHO-86 and NOPHO-92. Leukemia 2002;16:2037-45.
20. Roman-Gomez J, Castillejo JA, Jimenez A, et al: 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21 (CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 2002;99:2291-6.
21. Sherr CJ, The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731-7.
22. Ferrando AA, Neuberg DS, Staunton J, et al: Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002;1:75-87.
23. Armstrong SA, Staunton JE, Silverman LB, et al: MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002;30:41-7.
24. Yeoh EJ, Ross ME, Shurtleff SA, et al: Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002;1:133-43.
25. Cheok MH, Yang W, Pui CH, et al: Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 1002;34:85-90.
26. Greaves MF, Wiemels J: origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 2003;3:639-49.
27. Greaves MF, Maia AT, Wiemels JL, Ford AM: Leukemia in twins: lessons in natural history. Blood 2003;102:2321-33.
28. Wiemels JL, Leonard BC, Wang Y, et al: Site-specific translocation and evidence of postnatal origin of the t(1;19)E2A-PBX1 fusion in childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2002;99:15101-6.
29. Mori H, Colman SM, Xiao Z, et al: Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc Natl Acad Sci USA 2002;99:8242-7.
30. Pui CH, Relling MV: Topoisomerase II inhibitor-related acute myeloid leaukemia. Br J Haematol 2000;109:13-23.
31. Biondi A, Cimino G, Pieters R, Pui CH: Biological and therapeutic aspects of infant leukemia. Blood 2000;96:24-33.
32. Alexander FE, Patheal SL, Biondi A, et al: Tranplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res 2001;61:2542-6.
33. Chen CL, Liu Q, Pui CH, et al: Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood 1997;89:1701-7.
34. Davies SM, Bhatia S, Ross JA, et al: Glutathione S-transferase genotypes, genetic, susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 2002;100: 67-71.
35. Krajinovic M, Sinnet H, Richer C, Labuda D, Sinnet D: Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int J Cancer 2002;97:230-6.
36. Smith MT, Wang Y, Skibola CF, et al: Low NAD(P)H: quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood 2002;100:4590-3.
37. Franco RF, Simões BP, Tone LG, et al: The methylenetetrahydrofolate reductase C677T gene polymorphism decreases the risk of childhood acute lymphocytic leukaemia. Br J Haematol 2001;115:616-8.
38. Wiemels JL, Smith RN, Taylor GM, et al: Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtype of childhood acute leukemia. Proc Natl Acad Sci USA 2001;98:4004-9.
39. Skibola CF, Smith MT, Hubbard A, et al: Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood 2002; 99:3786-91.
40. Pui CH, Sallan S, Relling MV, Masera G, Evans WE: International childhood acute lymphoblastic Leukemia workshop: Sausalito CA, 30 November-1 December 2000. Leukemia 2001;15:707-15.
41. Pui CH, Campana D, Evans WE: Childhood acute lymphoblastic leukaemia - current status and future perspectives. Lancet Oncol 2001;2:597-607.
42. Pollock BH, DeBaun MR, Camitta BM, et al: Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group Study. J Clin Oncol 2000; 18:813-23.
43. Bhatia S, Sather HN, Heerema NA, Trigg ME, Gaynors PS, Robison LL: Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood 2002;100:1957-64.
44. Goldberg JM, Silverman LB, Levy DE, et al: Childhood T-cell acute lymphoblastic leukemia: The Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 2003;21:3616-22.
45. Pui CH, Relling MV, Campana D, Evans WE: Childhood acute lymphoblastic leukemia. Rev Clin Exp Hematol 2002;62: 161-80.
46. Pui CH, Relling MV, Evans WE. Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2003;15:741-56.
47. Evans WE, Relling MV, Rodman JH et al: Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J. Med 1998;338:499-505.
48. Relling MV, Hancock ML, Boyett JM, et al: Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 1999;93:2817-23.
49. relling MV, Pui CH, Sandlund JT, et al: Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukemia. Lancet 2000;356:285-90.
50. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2003;38:111-80.
51. Relling MV, Dervieux T: Pharmacogenetics and cancer therapy. Nat Rev Cancer 2001;1:99-108.
52. Evans WE, McLeod HL: Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49.
53. relling MV, Hancock ML, Rivera GK, et al: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999;91: 2001-8.
54. Relling MV, Rubnitz JE, Rivera GK, et al: High incidence of secondary brain tumors after radiotherapy and antimetabolites. Lancet 1999;354:34-9.
55. Bo J. Schrøder H, Kristinsson C, et al: Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer 1999;86:1080-6.
56. Krajinovic M, Costea I, Chiasson S: Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 2002;359:1033-4.
57. Urano W, Taniguchi A, Yamanaka H, et al: Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogentics 2002; 12:183-90.
58. Ulrich CM, Yasui Y, Storb R, et al: Pharmacogenetics of methotrexatee: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001;98:231-4.
59. Pui CH: Risk assessment in acute lymphoblastic leukemia: beyond leukemia cell characteristics. J Peditr Hematol Oncol 2001;23:405-8.
60. Pui Ch, Campana D: New definition of remission in childhood acute lymphoblastic leukemia. Leukemia 2001;14:783-5.
61. Pui Ch, Relling MV, Sandlund JT, et al: Rationale and design of total therapy study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol 2004;83(Suppl 1):S124-6.
62. Coustan-Smith E, Sancho J, Hancock ML, et al: Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002;100: 2399-402.
63. Pui CH, Schrappe M, Masera G, et al: Ponte di Legno Working Group: statement on the right of children with leukemia to have full access to essential treatment and report of the Sixth International Childhood Acute Lymphoblastic Leukemia Workshop. Leukemia. In press 2004.
64. Pui CH, Chessells JM, Camitta B, et al: Clinical heterogeinity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia 2003;17:700-6.
65. Liang DC, Hung IJ, Yang CP, et al: Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: a report from the Taiwan Pediatric Oncology Group. Leukemia 1999;13: 155-60.
66. Abshire TC, Pollock BH, Billet Al, et al: Wekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 2000;96:1709-15.
67. Duval M, Suciu S, Ferster A, et al: Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a ramdomized European Organisation for Research and Treatment of Cancer - Children's Leukemia Group phase 3 trial. Blood 2002;99:2734-9.
68. Hak LJ, Relling MV, Cheng C, et al: Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Blood. In press 2004.
69. Mitchell CD, Kinsey S, Vora AJ, Richards S, Eden T: MRC ALL97/99 - a randomized comparison of dexamethasone versus prednisolone and thioguanine versus mercaptopurine in the treatment of childhood acute lymphoblastic leukemia. Blood 2002;100(No. 11, part 1 of 2 parts):156a.
70. Bostrom BC, Sensel MR, Sather HN, et al: Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the children's Cancer group. Blood 2003;101:3809-17.
71. Hurwitz CA, Silverman LB, Schorin MA et al: Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 2000; 88:1964-9.
72. Pui CH, Mahmoud HH, Wiley JM, et al: Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001;19: 697-704.
73. Pui CH, Jeha S, Irwin D, Camitta B: Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001;15:1505-9.
74. Goldman S, Holcenberg JS, Finklestein JZ, et al: A randomized comparison between rasburicase and allopurinol in clidren with lyphoma and leukemia at high risk of tumor lysis. Blood 2001; 97:2998-3003.
75. Clarke, M, Gaynon P, Hann I, et al: CNS-directed therapy for childhood acute lymphoblastic leukemia: childhood ALL collaborative group overview of 43 randomized trials. J Clin Oncol 2003;21:1798-809.
76. Silverman LB, Declerck L, Gelber RD, et al: Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia 2000;14:2247-56.
77. Stork LC, Sather H, Hutchinson RJ, et al: Comparison of mercaptopurine (MP) with thioguanine (TG) and IT methotrexate (ITM) with IT "Triples" (ITT) in children with SR-ALL: results of CCg-1952. Blood 2002;100(No. 11, part 1 of 2 parts):156a.
78. Harms DO, Göbe U, Spaar HJ, et al: Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. Blood 2003;102:2736-40.
79. Lange BJ, Bostrom BC, Cherlow JM, et al: Double-delayed intensification improves event-free surrvival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2002;99:825-33.
80. Aricò M, Vasecchi MG, Conter V, et al: Improved outcome in high risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood 2002;100:420-6.
81. Nachman JB, Sather HN, Sensel MG, et al: Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998;338:1663-71.
82. Toyoda Y, Manabe A, Tsuchida M, et al: Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 2000; 18:1508-16.
83. Tsuchida M, Ikuta K, Hanada R, et al: Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981-1995. Leukemia 2000;14:2295-306.
84. Schrappe M, Reiter A, Zimmermann M, et al: long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia 2000;14:2205-22.
85. Gajjar A, Harrison PL, Sandlund JT, et al: Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood 2000;96:3381-4.
86. Pui CH: Cure of childhood ALL: exacting a lower toll. Blood 2002;99:4255.
87. Manera R, Ramirez I, Mullins J, Pinkel D: Pilot studies of species-specific chemotherapy of childhood acute lymphoblastic leukemia using genitype and immunophenotype. Leukemia 2000;14:1345-61.
88. Pui CH: Toward optimal central nervous system-directed treatment in childhood acute lymphoblastic leukemia. J Clin Oncol 2003:21:179-81.
89. Marie JP: Drug resistance in hematologic malignancies. Curr Opin Oncol 2001;13:463-9.
90. Armstrong SA, Kung AL, Mabon ME, et al: Inhibition of FLT3 in MLL. Validation of a therapuetic target identified by gene expression based classification. Cancer Cell 2003;3:173-83.
91. Ross ME, Zhou X, Song G, et al: Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003; 102:2951-59.
92. McManus MT, Sharp PA: gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002;3:737-47.
93. MacBeath G. Protein microarrays and proteomics. Nat Genet 2002;32:526-32.
94. Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344: 1038-42.
95. Druker BJ. STI571 (Gleevec ™) as a paradigm for cancer therapy. Trends Mol Med 2002;8:S14-8.
96. Lee S, Kim DW, Kim YJ, et al: Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2003;102:3068-70.
97. Sawyers CL: Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 2002; 1:413-5.
98. levis M, Small D: FLT3: IT Does matter in leukemia. Leukemia 2003;17:1738-52.
99. Batova A, Shao LE, Dicciani MB, et al: The histone deacetylase inhibitor AN-9 has selective toxicitty to acute leukemia and drug-resistant primary leukemia and cancer cells lines. Blood 2002; 100:3319-24.
100. Johnstone RW, Licht JD: Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? cancer Cell 2003; 4:13-8.